Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesKiromic Biopharma Inc

Kiromic Biopharma Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
None USD 0.00(0%)
Last update at 2026-11-09T18:16:24.718252Z
Market Cap
4.94M

Momentum Score

…

Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has a license agreement with Longwood University; and a research and development collaboration agreement with Molipharma, S.R.L. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.16
Low
4.08
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Kiromic Biopharma Inc is a clinical-stage biotechnology company listed on NASDAQ that develops engineered cell- and immune-based therapies; publicly available disclosures are limited. Long-term growth drivers may include clinical-program advancement, regulatory milestones, strategic collaborations and protection of intellectual property, which could support value creation for investors monitoring clinical and development progress.
Primary risks include clinical trial setbacks, need for additional capital and potential dilution, regulatory and approval uncertainty, and intense competition within oncology and cell therapy spaces.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
22.76
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-1.70
ROE
-1129.81%
Net Debt
12.34M
ROCE
379.01%
Diluted EPS TTM
-7.42

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -34.73M -25.59M -19.20M -3.73M -3.82M
Net income -38.18M -25.65M -19.20M -3.75M -3.82M
Selling general administrative 17.19M 13.94M 14.14M 2.50M 1.76M
Reconciled depreciation 1.67M 0.47M 0.20M 0.09M 0.08M
Ebit -31.11M -25.74M -19.20M -3.71M -3.18M
Ebitda -29.44M -24.78M -19.00M -3.62M -3.10M
Depreciation and amortization 1.67M 0.95M 0.20M 0.09M 0.08M
Operating income -31.11M -25.74M -19.20M -3.71M -3.18M
Other operating expenses 31.11M 25.31M 19.20M 3.71M 3.18M
Interest expense 0.17M 0.01M 0.00M 0.02M 0.63M
Tax provision - - - 0.00M 0.00M
Net interest income -0.17M -0.01M -0.00M -0.02M -0.63M
Income tax expense 3.45M 0.07M 0.00M 0.02M -
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 31.11M 25.31M 19.20M 3.71M 3.18M
Total other income expense net -3.62M 0.15M -0.00M -0.02M -0.63M
Net income from continuing ops -34.73M -25.59M -19.20M -3.73M -3.82M
Net income applicable to common shares -34.73M -25.81M -19.20M -3.98M -3.82M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 12.17M 11.97M 30.73M 12.83M 2.65M
Other current assets 1.23M 1.04M 1.70M 0.59M 0.09M
Total liab 21.29M 17.74M 3.41M 1.47M 0.67M
Total stockholder equity -9.12M -5.77M 27.32M 11.36M 1.98M
Other current liab 17.61M 1.02M 0.74M 0.33M 0.22M
Common stock 0.00M 0.00M 0.01M 0.00M -
Capital stock 0.00M 0.00M 0.01M 0.00M 10.44M
Retained earnings -122.90M -101.95M -67.22M -41.63M -22.43M
Other assets - 0.02M 0.03M 0.00M 0.02M
Cash 3.20M 0.65M 25.35M 10.15M 1.93M
Total current liabilities 20.38M 13.28M 3.41M 1.47M 0.67M
Current deferred revenue -14.00M - - - -
Net debt 12.34M 8.77M -24.90M -9.68M -1.93M
Short term debt 14.63M 4.95M 0.45M 0.47M -
Short long term debt 14.00M 4.37M 0.45M 0.47M -
Short long term debt total 15.54M 9.41M 0.45M 0.47M -
Other stockholder equity 113.77M 96.17M 94.53M 52.99M 13.96M
Property plant equipment - 10.25M 3.63M 2.07M 0.59M
Total current assets 4.43M 1.69M 27.07M 10.74M 2.04M
Net tangible assets - -5.77M 27.32M 11.36M -8.46M
Net receivables - 0.00M 0.02M - -
Long term debt - 2.91M - - -
Inventory - - - 0.00M 0.02M
Accounts payable 2.14M 7.31M 2.21M 0.67M 0.45M
Accumulated other comprehensive income -0.00M - - - -0.36M
Common stock total equity - - - 0.00M -
Non currrent assets other 0.02M 0.02M 0.03M 0.02M 0.02M
Non current assets total 7.74M 10.28M 3.66M 2.09M 0.61M
Capital lease obligations 1.54M 2.13M - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -4.87M -1.81M -1.46M -0.30M -0.14M
Change to liabilities 3.79M 1.41M -0.01M 0.29M -0.00M
Total cashflows from investing activities -4.87M -1.81M -1.46M -0.30M -0.14M
Net borrowings 4.10M 0.09M 0.47M 0.25M 0.72M
Total cash from financing activities 3.90M 37.34M 15.81M 4.76M 1.62M
Change to operating activities 0.56M -0.71M -0.39M -0.13M 0.34M
Net income -34.73M -25.59M -19.20M -3.73M -3.82M
Change in cash -24.71M 15.20M 8.22M 1.54M -0.67M
Begin period cash flow 25.35M 10.15M 1.93M 0.38M 1.05M
End period cash flow 0.65M 25.35M 10.15M 1.93M 0.38M
Total cash from operating activities -23.75M -20.32M -6.13M -2.91M -2.15M
Issuance of capital stock 0.00M 40.00M 18.00M 4.50M 0.90M
Depreciation 1.67M 0.47M 0.20M 0.09M 0.08M
Change to inventory - - 0.02M -0.01M -0.01M
Change to account receivables 0.02M 0.01M 0.01M -0.08M -0.02M
Other cashflows from financing activities 4.41M -2.09M 0.99M -0.30M 1.62M
Change to netincome 4.93M 4.09M 13.27M 0.54M 1.27M
Capital expenditures 4.88M 1.89M 1.46M 0.30M 0.14M
Change in working capital 4.37M 0.71M -0.39M 0.18M 0.32M
Stock based compensation 1.24M 3.76M 13.25M 0.52M 0.63M
Other non cash items 3.70M 0.32M 0.00M 0.02M 0.63M
Free cash flow -28.63M -22.22M -7.58M -3.22M -2.29M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
NVO
Novo Nordisk A/S		 1.03
2.56%		 41.34 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.49
0.27%		 548.58 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 18.16
2.01%		 922.51 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Kiromic Biopharma Inc

Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has a license agreement with Longwood University; and a research and development collaboration agreement with Molipharma, S.R.L. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.

7707 Fannin Street, Houston, TX, United States, 77054

832 968 4888

https://www.kiromic.com

35

Name Title Year Born
Mr. Pietro Bersani CPA, J.D. CEO & Director 1968
Dr. Scott Dahlbeck M.D., Pharm.D., PharmD Chief of Staff 1962
Mr. Daniel Clark Chief Financial Officer 1989
Dr. Leonardo Mirandola Ph.D. Chief Scientific Officer NA
Dr. Michael Ryan Ph.D. Chief Bioinformatics Research Computing Officer 1967
Mr. Brian Hungerford Chief Financial Officer 1976
Dr. Leonardo Mirandola Ph.D. Chief Scientific Officer & Interim COO 1982

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.94
+37.96%
MOON
CAD 4.90
+11.11%
UCU
CAD 2.37
+10.75%
ANRG
CAD 1.90
+10.47%
EPRX
CAD 10.71
+10.30%
DIV
CAD 3.77
-7.37%
CSU
CAD 3281.97
-6.93%
LMN
CAD 26.62
-5.23%
TOI
CAD 99.75
-4.80%
GRZ
CAD 5.05
-4.72%

Equity Sectors*

  • Basic Materials

    +4.21%

  • Communication Services

    -0.63%

  • Consumer Cyclical

    +1.12%

  • Consumer Defensive

    +0.09%

  • Energy

    +1.91%

  • Financial Services

    +1.63%

  • Healthcare

    +1.49%

  • Industrials

    +3.56%

  • Real Estate

    +0.66%

  • Technology

    +1.84%

  • Utilities

    +1.24%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…